AU Patent

AU2019358249A1 — Ophthalmic composition for treatment of dry eye disease

Assigned to Novaliq GmbH · Expires 2021-05-13 · 5y expired

What this patent protects

The invention provides ophthalmic compositions comprising 0.1 % (w/ v) cyclosporine dissolved in l-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

USPTO Abstract

The invention provides ophthalmic compositions comprising 0.1 % (w/ v) cyclosporine dissolved in l-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019358249A1
Jurisdiction
AU
Classification
—
Expires
2021-05-13
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.